

## SECUKINUMAB solution for injection (Cosentyx®) for enthesitis-related arthritis or juvenile psoriatic arthritis

**The Cheshire and Merseyside Area Prescribing Group does not currently recommend the prescribing of SECUKINUMAB solution for injection (Cosentyx®) for enthesitis-related arthritis or juvenile psoriatic arthritis.**

### GREY

Secukinumab has been granted a license extension and is now indicated alone, or in combination with methotrexate, for:

- > The treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.<sup>[1]</sup>
- > The treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.<sup>[1]</sup>

**NHS England is the responsible commissioner for these indications for treatment of children. However, the integrated care board (ICB) is the responsible commissioner for these indications for treatment of adults.**

NICE have currently suspended this [technology appraisal \(TA\)](#). Therefore, this recommendation will be reviewed when further information is available on the NICE website.

In the meantime, treatment of enthesitis-related arthritis and juvenile psoriatic arthritis should continue to follow national guidance, local pathways and local formulary choices:

- > NICE guideline [NG65]: [Spondyloarthritis in over 16s: diagnosis and management](#) (updated 02 June 2017)
- > Cheshire APG Formulary Chapter 10: [Musculoskeletal and joint disease](#)
- > Pan Mersey APC Formulary Chapter 10: [Musculoskeletal and joint diseases](#)  
Pan Mersey APC Guideline [Juvenile idiopathic arthritis: biologic agents in the management of](#) (updated 27 April 2022)

### References

1. Novartis Pharmaceuticals UK Ltd. Summary of Product Characteristics; [Cosentyx 75mg solution for injection in pre-filled syringe](#), 07 November 2022. Accessed 20 June 2023.

**Note:** Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.